| |
| |
|
| Insider
Information: |
Rosenwald Lindsay A Md |
| Relationship: |
Director |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
13 |
|
| Direct
Shares |
37,631,451 |
|
|
Indirect Shares
|
13,489,834 |
|
|
| Direct
Value |
$67,681,835 |
|
|
|
Indirect Value
|
$48,000,247 |
|
|
| Total
Shares |
51,121,285 |
|
|
| Total
Value |
$115,682,082 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
8
|
0
|
|
Stock
price went up :
|
2
|
0
|
| Stock
price went down : |
6
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
 -25.3%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Genta Inc De |
GNTAQ |
10% Owner |
2003-07-14 |
21,531,885 |
2004-02-13 |
656,191 |
Premium* |
|
|
Soligenix Inc Common |
SNGX |
10% Owner |
2004-02-12 |
0 |
2004-02-12 |
3,230,922 |
Premium* |
|
|
TG Therapeutics Inc |
TGTX |
10% Owner |
2005-05-11 |
2,649,321 |
2005-05-11 |
2,682,507 |
Premium* |
|
|
Cypress Bioscience Inc |
CYPB |
10% Owner |
2004-01-09 |
0 |
2004-01-13 |
2,210,848 |
Premium* |
|
|
Keryx Biopharmaceuticals Inc |
KERX |
Director |
2006-05-22 |
1,735,863 |
2006-05-22 |
320,786 |
Premium* |
|
|
Alaunos Therapeutics |
TCRT |
10% Owner |
2005-09-13 |
476,678 |
2005-09-13 |
737,777 |
Premium* |
|
|
Chem Rx Corporation |
CHRXU |
Officer, Director, 10%... |
2005-10-21 |
584,375 |
2005-10-21 |
584,375 |
Premium* |
|
|
Velcera Inc |
VLCR |
10% Owner |
2006-01-17 |
121,205 |
|
0 |
Premium* |
|
|
Fortress Biotech, Inc. |
FBIO |
President, CEO & Chair... |
2024-01-05 |
2,863,905 |
2017-01-01 |
2,367,666 |
Premium* |
|
|
National Holdings Corp |
NHLD |
10% Owner |
2016-09-12 |
7,037,482 |
2016-09-12 |
522,292 |
Premium* |
|
|
Checkpoint Therapeutics, Inc. |
CKPT |
Director |
2024-05-14 |
132,174 |
2017-07-10 |
0 |
Premium* |
|
|
Avenue Therapeutics, Inc. |
ATXI |
Director |
2023-09-08 |
354,318 |
|
0 |
Premium* |
|
|
Journey Medical Ord Shs |
DERM |
Director |
2024-03-25 |
144,245 |
2024-03-25 |
176,470 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
164 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 7
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| GNTAQ |
Genta Inc De |
10% Owner |
– – • |
2004-02-13 |
4 |
D |
$0.00 |
$0 |
I/I |
(9,359,582) |
0 |
|
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Director |
– • • |
2004-11-23 |
4 |
S |
$11.51 |
$440,707 |
I/I |
(38,300) |
0 |
|
- |
|
| ATXI |
Avenue Therapeutics, Inc. |
Director |
– • – |
2017-03-13 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
10,000 |
|
- |
|
| CKPT |
Checkpoint Therapeutics, ... |
Director |
– • – |
2017-07-10 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
10,000 |
0 |
- |
|
| ATXI |
Avenue Therapeutics, Inc. |
Director |
– • – |
2017-10-04 |
4 |
B |
$5.60 |
$12,320 |
D/D |
2,200 |
12,200 |
2.39 |
- |
|
| DERM |
Journey Medical Ord Shs |
Director |
– • – |
2022-07-21 |
4 |
A |
$0.00 |
$0 |
D/D |
14,245 |
14,245 |
0 |
- |
|
| ATXI |
Avenue Therapeutics, Inc. |
Director |
– • – |
2017-10-05 |
4 |
B |
$5.60 |
$19,880 |
D/D |
3,550 |
15,750 |
2.39 |
- |
|
| ATXI |
Avenue Therapeutics, Inc. |
Director |
– • – |
2017-10-06 |
4 |
B |
$5.63 |
$16,327 |
D/D |
2,900 |
18,650 |
2.39 |
- |
|
| ATXI |
Avenue Therapeutics, Inc. |
Director |
– • – |
2017-10-09 |
4 |
B |
$5.40 |
$7,290 |
D/D |
1,350 |
20,000 |
2.39 |
- |
|
| ATXI |
Avenue Therapeutics, Inc. |
Director |
– • – |
2018-06-08 |
4 |
B |
$4.34 |
$22,716 |
D/D |
5,234 |
25,234 |
2.39 |
- |
|
| CKPT |
Checkpoint Therapeutics, ... |
Director |
– • – |
2018-06-14 |
4 |
A |
$0.00 |
$0 |
D/D |
16,448 |
26,448 |
0 |
- |
|
| CKPT |
Checkpoint Therapeutics, ... |
Director |
– • – |
2018-11-07 |
4 |
B |
$2.12 |
$4,452 |
D/D |
2,100 |
28,548 |
2.31 |
- |
|
| ATXI |
Avenue Therapeutics, Inc. |
Director |
– • – |
2018-06-01 |
4/A |
B |
$4.15 |
$36,003 |
D/D |
8,666 |
28,666 |
2.39 |
- |
|
| ATXI |
Avenue Therapeutics, Inc. |
Director |
– • – |
2018-06-04 |
4/A |
B |
$4.19 |
$15,921 |
D/D |
3,800 |
32,466 |
2.39 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Director |
– • • |
2004-11-22 |
4 |
S |
$11.77 |
$529,650 |
I/I |
(45,000) |
38,300 |
|
- |
|
| FBIO |
Fortress Biotech, Inc. |
PRESIDENT, CEO |
• • • |
2017-11-06 |
4 |
B |
$25.00 |
$1,000,000 |
D/D |
40,000 |
40,000 |
3.23 |
- |
|
| ATXI |
Avenue Therapeutics, Inc. |
Director |
– • – |
2018-06-05 |
4/A |
B |
$4.28 |
$35,949 |
D/D |
8,400 |
40,866 |
2.39 |
- |
|
| ATXI |
Avenue Therapeutics, Inc. |
Director |
– • – |
2018-06-06 |
4/A |
B |
$4.35 |
$39,576 |
D/D |
9,100 |
49,966 |
2.39 |
- |
|
| CKPT |
Checkpoint Therapeutics, ... |
Director |
– • – |
2023-06-13 |
4 |
A |
$0.00 |
$0 |
D/D |
17,483 |
50,123 |
0 |
- |
|
| ATXI |
Avenue Therapeutics, Inc. |
Director |
– • – |
2018-06-07 |
4/A |
B |
$4.32 |
$63,969 |
D/D |
14,800 |
64,766 |
2.39 |
- |
|
| ATXI |
Avenue Therapeutics, Inc. |
Director |
– • – |
2018-06-08 |
4/A |
B |
$4.34 |
$22,727 |
D/D |
5,234 |
70,000 |
2.39 |
- |
|
| CKPT |
Checkpoint Therapeutics, ... |
Director |
– • – |
2018-11-08 |
4 |
B |
$2.24 |
$108,044 |
D/D |
48,234 |
76,782 |
2.39 |
- |
|
| KERX |
Keryx Biopharmaceuticals ... |
Director |
– • • |
2004-11-19 |
4 |
S |
$12.14 |
$252,470 |
I/I |
(20,800) |
83,300 |
|
- |
|
| ATXI |
Avenue Therapeutics, Inc. |
Director |
– • – |
2018-08-07 |
4 |
GA |
$0.00 |
$0 |
D/D |
14,663 |
84,663 |
0 |
- |
|
| FBIO |
Fortress Biotech, Inc. |
PRESIDENT, CEO & CHAIRMAN |
• • • |
2020-08-26 |
4 |
B |
$18.00 |
$945,000 |
D/D |
52,500 |
92,500 |
3.23 |
% |
|
164 Records found
|
|
Page 1 of 7 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
